Skip to main content
G

GUANGZHOU WONDFO BIOTECH CO.,LTD — Investor Relations & Filings

Ticker · 300482 LEI · 3003000XGXAINFEXYE82 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300482

About GUANGZHOU WONDFO BIOTECH CO.,LTD

https://www.wondfo.com.cn

Guangzhou Wondfo Biotech Co., Ltd. specializes in the research, development, and manufacturing of rapid diagnostic products and point-of-care testing (POCT) solutions. The company provides a comprehensive range of diagnostic reagents and instruments across multiple clinical applications, including infectious diseases, cardiovascular health, oncology, diabetes, and pregnancy testing. Its technological capabilities encompass lateral flow assays, fluorescence immunoassays, molecular diagnostics, and chemiluminescence. These platforms support healthcare providers in delivering timely clinical decisions for chronic disease management and emergency diagnostics. With a focus on accessibility and precision, the company supplies diagnostic tools to a global network of medical facilities and laboratories, emphasizing continuous innovation in the field of medical diagnostics.

Recent filings

Filing Released Lang Actions
第五届董事会第二十三次会议决议公告
Regulatory Filings Classification · 1% confidence The document is a corporate announcement of the resolutions passed at the 23rd meeting of the 5th Board of Directors, listing agenda items (approval of various reports, financial statements, profit distribution, re-appointment of auditors, etc.) and voting results. It is not itself an annual or quarterly report, nor a presentation, nor an earnings release, nor does it announce board or management changes. It is a routine regulatory announcement of board meeting decisions that does not fit a more specific category, so it falls under the general Regulatory Filings (RNS) category.
2026-04-22 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 1% confidence The document is titled '2026年第一季度报告' (2026 First Quarter Report) for Guangzhou Wondfo Biotech Co., Ltd. It contains comprehensive financial statements, including the Consolidated Balance Sheet, Consolidated Income Statement, and Consolidated Cash Flow Statement for the first quarter of 2026. It is not an announcement of a report, but the report itself, and it contains substantive financial data. Therefore, it is classified as an Interim/Quarterly Report. Q1 2026
2026-04-22 Chinese
2025年度募集资金存放与使用情况专项报告
Regulatory Filings Classification · 1% confidence The document is a Special Report on the Deposit and Use of Proceeds (“募集资金存放与使用情况专项报告”), prepared under China Securities Regulatory Commission and Shenzhen Stock Exchange rules. It details the amounts raised in 2022, actual use during 2025, cash management, account balances, governance procedures, approvals, and tables. It is not an Annual Report, Earnings Release, Call Transcript, or any governance change notice. It is not merely announcing that a report is published (so not RPA), but is the full compliance report itself. No specific category like “fund usage report” exists among the predefined types. Therefore this falls into the fallback “Regulatory Filings” category (RNS).
2026-04-22 Chinese
广州万孚生物技术股份有限公司利润分配方案
Notice of Dividend Amount Classification · 1% confidence The document is an interim announcement (‘临时公告’) detailing the company’s 2025 profit distribution plan, specifying a cash dividend of RMB 2.2 per 10 shares, total dividend amount, approvals by the board and audit committee, and timing notes. This is exactly a Notice of Dividend Amount, matching the DIV category.
2026-04-22 Chinese
万孚生物2025年度内部控制审计报告
Audit Report / Information Classification · 1% confidence The document is an internal control audit report issued by a registered accounting firm (BDO China Shu Lun Pan CPA LLP) on the effectiveness of Guangzhou Wanfubio’s financial reporting internal controls for the year ended Dec 31, 2025. It is a standalone audit report on internal controls, not an announcement of a report or results, thus it fits the Audit Report / Information category.
2026-04-22 Chinese
2025年度内部控制自我评价报告
Audit Report / Information Classification · 1% confidence The document is a standalone internal control self-evaluation report (“内部控制自我评价报告”) by the company covering its internal control systems and defect assessments for the fiscal period ending December 31, 2025. It is not a general announcement of publication, not an annual or interim financial report, nor a board change or earnings release. It is a detailed internal audit/evaluation report on the company’s control environment, fitting the “Audit Report / Information” category (Code: AR).
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.